Comply With Revised Prices Of 137 Anti-Cancer Drugs: NPPA, Pg12

Key Highlights:

• The National Pharmaceutical Pricing Authority (NPPA) has issued a warning regarding non-compliance with the revised prices of 137 non-scheduled anti-cancer drugs.
• Penal action will be taken against those failing to adhere to the new prices, which came into effect on November 9.
• The government capped the trade margin on these 137 medicines at 30% to make them more affordable.
• State drug controllers have been directed to monitor prices strictly and submit action taken reports by November 16.

Detailed Insights:

• The NPPA is responsible for fixing and revising the prices of scheduled and non-scheduled drugs under the Drugs (Prices Control) Order.
• Non-scheduled drugs are those not included in the National List of Essential Medicines (NLEM), giving manufacturers more flexibility in pricing.
• Trade margin capping aims to reduce the final retail price of medicines by limiting the profit margins of distributors and retailers.
• This measure is expected to significantly reduce the cost of these crucial anti-cancer drugs, improving accessibility for patients.
• The Pharma Sahi Daam app and a dedicated helpline are available for consumers to report instances of overcharging or non-availability of medicines.

Key Concepts Involved:

• National Pharmaceutical Pricing Authority (NPPA): A government regulatory body that fixes and revises drug prices in India.
• Non-scheduled drugs: Medicines not listed in the National List of Essential Medicines (NLEM), allowing for more flexible pricing.
• Trade Margin Capping: A regulatory mechanism to limit the profit margins of distributors and retailers on specific products.
• Drugs (Prices Control) Order: A legal framework under which the NPPA operates to regulate drug prices in India.